

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR ANY JURISDICTION OUTSIDE SINGAPORE



(Company Registration Number 202227593G)
(Incorporated in Singapore on 8 August 2022)

Stabilisation Announcement

Oversea-Chinese Banking Corporation Limited and UBS AG, Singapore Branch are the joint issue managers for the Offering (the **"Joint Issue Managers"**). Jefferies Singapore Limited, Oversea-Chinese Banking Corporation Limited, UBS AG, Singapore Branch, DBS Bank Ltd. and United Overseas Bank Limited are the joint bookrunners and underwriters for the Offering (the **"Joint Bookrunners and Underwriters"**).

*Capitalised terms used herein, unless otherwise defined, have the meanings as defined in the prospectus of Foundation Healthcare Holdings Limited (the **"Company"**) dated 1 July 2026 and registered with the Monetary Authority of Singapore on 1 July 2026 (the **"Prospectus"**).*

For the purpose of Regulation 3A(2)(g) of the Securities and Futures (Market Conduct) (Exemptions) Regulations 2006, it is hereby announced that in connection with the Offering, SeaTown Private Capital Master Fund (the **"Over-allotment Option Grantor"**) has granted the Joint Bookrunners and Underwriters an over-allotment option (the **"Over-allotment Option"**) exercisable by UBS AG, Singapore Branch (the **"Stabilising Manager"**) (or any of its affiliates or other persons acting on its behalf), in full or in part, on one or more occasions, to purchase from the Over-allotment Option Grantor up to an aggregate of 24,276,300 Shares at the Offering Price, representing approximately 14.9% of the total number of Offering Shares, solely to cover the over-allotment of Shares (if any) made in connection with the Offering.

The Over-Allotment Option is exercisable from the date of admission of the Shares of the Company to the Official List of the SGX-ST (the **"Listing Date"**) until the earlier of (i) the date falling 30 days from the Listing Date; or (ii) the date when the Stabilising Manager (or its affiliates or other persons acting on its behalf) has bought, on the SGX-ST, an aggregate of 24,276,300 Shares, representing approximately 14.9% of the total number of Offering Shares, to undertake stabilising actions.

The exercise of the Over-Allotment Option will not increase the total number of Shares outstanding.

In connection with the Offering, the Stabilising Manager (or any of its affiliates or other persons acting on its behalf) may over-allot Shares or effect transactions which stabilise or maintain the market price of the Shares at levels that might not otherwise prevail in the open market. However, there is no assurance that the Stabilising Manager (or any of its affiliates or other persons acting on its behalf) will undertake stabilising action. The number of Shares that the Stabilising Manager may buy to undertake stabilising actions shall not exceed 24,276,300 Shares, representing approximately 14.9% of the total number of Offering Shares. Such transactions may commence on or after the Listing Date, and, if commenced, may be discontinued at any time at the Stabilising

Manager's sole discretion and must not be effected after the earlier of (i) the date falling 30 days from the Listing Date; or (ii) the date when the Stabilising Manager (or its affiliates or other persons acting on its behalf) has bought, on the SGX-ST, an aggregate of 24,276,300 Shares, representing approximately 14.9% of the total number of Offering Shares, in undertaking stabilising actions. Such transactions may be effected on the SGX-ST and in other jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws and regulations, including the Securities and Futures Act 2001 of Singapore, and any regulations thereunder.

An announcement will be made if and when the Over-allotment Option is exercised.

Issued jointly by

Oversea-Chinese Banking Corporation Limited
UBS AG, Singapore Branch
Jefferies Singapore Limited
DBS Bank Ltd.
United Overseas Bank Limited
(as the Joint Bookrunners and Underwriters)

For and on behalf of
Foundation Healthcare Holdings Limited
(Company Registration Number 202227593G)

7 July 2026

IMPORTANT NOTICE

This announcement is for information only and does not constitute or form part of an offer, invitation or solicitation of any offer to purchase or subscribe for the Shares in Singapore or any other jurisdiction nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This announcement is qualified in its entirety by, and should be viewed in conjunction with, the full text of the Prospectus in relation to the Offering.

The value of the Shares and the income derived from them may fall as well as rise. The Shares are not obligations of, deposits in, or guaranteed by the Company, the Joint Issue Managers, the Joint Bookrunners and Underwriters or any of their respective affiliates. An investment in the Shares is subject to investment risks, including the possible loss of the principal amount invested. Listing of the Shares on the SGX-ST does not guarantee a liquid market for the Shares.

The Offering Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with applicable state laws of any state or other jurisdiction of the United States. Accordingly, the Offering Shares are being offered and sold (a) outside the United States (including institutional and other investors in Singapore) in offshore transactions in reliance on Regulation S and (b) within the United States only to Qualified Institutional Buyers in reliance on Rule 144A under the U.S. Securities Act. There will be no public offer of Offering Shares in the United States. Any

failure to comply with this restriction may constitute a violation of securities laws in the United States and in other jurisdictions.

This announcement is not to be distributed or circulated outside of Singapore. Any failure to comply with this restriction may constitute a violation of state securities laws of the United States or the laws of any other jurisdiction.